Previous 10 | Next 10 |
2023-08-14 01:03:21 ET Summary COMPASS Pathways continues to make solid progress in its ambition to gain regulatory approval for COMP360 psilocybin-assisted therapy for treatment-resistant depression. The group has refined its strategy for the eventual monetization of COMP360, and...
2023-08-05 22:38:08 ET COMPASS Pathways plc (CMPS) Q2 2023 Earnings Conference Call August 03, 2023 08:00 AM ET Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - Chief Executive Officer Guy Goodwin - Chief Medical Off...
Research into psychedelics has revealed that the Default Mode Network (DMN), a series of interconnected regions in the brain that are involved in introspection, may play a role in how psychedelics deliver their effects. The DMN is associated with self-criticism and self-reflection and exhibit...
2023-08-04 00:00:35 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2023 Earnings Call Aug 03, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2023 Earnings Ca...
2023-08-03 09:39:30 ET COMPASS Pathways ADS press release ( NASDAQ: CMPS ): Q2 GAAP EPS of -$0.62 beats by $0.08 . Cash and cash equivalents were $148.2 million as of 30 June 2023, compared with $143.2 million as of 31 December 2022. For further details see: ...
LONDON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the second quarter 2023 and gave an updat...
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2023, and provide an update ...
2023-07-28 10:15:00 ET When a company is developing a novel therapy, sometimes good news takes an unusual form. For Compass Pathways , (NASDAQ: CMPS) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychol...
The Kentucky Opioid Abatement Advisory Commission has begun taking expert testimonies on the benefits of using psychedelics to treat opioid use disorder. Psychedelics have emerged as a potential alternative treatment to a wide variety of mental disorders in recent years, thanks to an influx of...
2023-07-26 08:45:24 ET Palm Beach, FL – July 26, 2023 – FinancialNewsMedia.com News Commentary – Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming yea...
News, Short Squeeze, Breakout and More Instantly...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...
New research has determined that psilocybin may impact the brain. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, it distorts an individual’s perception of time, among other changes. Researchers have observed that in animals, psilocyb...